CTIC Share Price

Open 4.28 Change Price %
High 4.45 1 Day 0.17 3.98
Low 4.28 1 Week -0.02 -0.45
Close 4.44 1 Month -0.43 -8.83
Volume 73887 1 Year 3.81 604.76
52 Week High 6.48
52 Week Low 0.31
CTIC Important Levels
Resistance 2 4.60
Resistance 1 4.53
Pivot 4.39
Support 1 4.35
Support 2 4.28
NASDAQ USA Most Active Stocks
SPWR 8.98 1.01%
TFSL 17.20 0.17%
RIGL 2.52 9.57%
ADP 102.70 -0.29%
ADP 102.70 -0.29%
ADP 102.70 -0.29%
ADP 102.70 -0.29%
FNFG 10.18 -0.20%
ASTI 0.00 0.00%
REGN 373.05 3.34%
More..
NASDAQ USA Top Gainers Stocks
TEAR 5.74 983.02%
CGEI 0.37 85.00%
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
IMGN 3.28 21.03%
VOXX 5.05 20.24%
HAUP 0.06 20.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Cell Therapeutics, Inc. (NASDAQ: CTIC)

CTIC Technical Analysis 3
As on 27th Feb 2017 CTIC Share Price closed @ 4.44 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.13 & Buy for SHORT-TERM with Stoploss of 3.47 we also expect STOCK to react on Following IMPORTANT LEVELS.
CTIC Target for February
1st Target up-side 6.17
2nd Target up-side 7.17
3rd Target up-side 8.17
1st Target down-side 3.33
2nd Target down-side 2.33
3rd Target down-side 1.33
CTIC Other Details
Segment EQ
Market Capital 134819600.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.celltherapeutics.com
CTIC Address
CTIC
3101 Western Avenue
Suite 600
Seattle, WA 98121
United States
Phone: 206-282-7100
Fax: 206-284-6206
CTIC Latest News
Interactive Technical Analysis Chart Cell Therapeutics, Inc. ( CTIC NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Cell Therapeutics, Inc.
CTIC Business Profile
Cell Therapeutics, Inc. (CTI) is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic ways to treats cancer. The Company is concentrating its efforts on treatments that target blood-related cancers where there is an unmet medical need. The Company is primarily focused on commercializing PIXUVRI (pixantrone) in the European Union for multiplies relapsed or refractory aggressive non-Hodgkin lymphoma (NHL), and conducting a Phase III clinical trial of pacritinib for the treatment of myelofibrosis. PIXUVRI is a novel aza-anthracenedione derivative that is structurally related to anthracyclines and anthracenediones, but does not appear to be associated with the same level of cardiotoxic effects.